BRPI0817597A2 - Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos - Google Patents

Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos

Info

Publication number: BRPI0817597A2
Authority: BR; Brazil
Prior art keywords: kit; preparation; well; pharmaceutical compositions; diaryl compounds
Prior art date: 2007-10-04

Application number

Other languages

English (en)

Inventor

Cyril Montagne

Anna Quattropani

Wolfgang Sauer

Agnes Bombrun

Original Assignee

Merck Serono Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-04

Filing date

2008-10-01

Publication date

2015-04-07

2008-10-01 Application filed by Merck Serono Sa filed Critical Merck Serono Sa

2015-04-07 Publication of BRPI0817597A2 publication Critical patent/BRPI0817597A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Neurology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Obesity (AREA)
AIDS & HIV (AREA)
Toxicology (AREA)
Psychiatry (AREA)

BRPI0817597 2007-10-04 2008-10-01 Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos BRPI0817597A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP07117925		2007-10-04
US99813607P	2007-10-09	2007-10-09
PCT/EP2008/063185 WO2009043890A1 (en)	2007-10-04	2008-10-01	Oxadiazole diaryl compounds

Publications (1)

Publication Number	Publication Date
BRPI0817597A2 true BRPI0817597A2 (pt)	2015-04-07

Family

ID=38961274

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0817597 BRPI0817597A2 (pt)	2007-10-04	2008-10-01	Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos

Country Status (15)

Country	Link
US (2)	US8404676B2 (pt)
EP (1)	EP2193126B1 (pt)
JP (3)	JP5727223B2 (pt)
KR (1)	KR20100083814A (pt)
CN (2)	CN101815707B (pt)
AR (1)	AR068730A1 (pt)
AU (1)	AU2008306886B2 (pt)
BR (1)	BRPI0817597A2 (pt)
CA (1)	CA2696829C (pt)
EA (1)	EA201070423A1 (pt)
ES (1)	ES2547877T3 (pt)
IL (1)	IL204520A (pt)
MX (1)	MX2010003614A (pt)
WO (1)	WO2009043890A1 (pt)
ZA (1)	ZA201001217B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2125797B1 (en)	2007-03-16	2014-01-15	Actelion Pharmaceuticals Ltd.	Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
WO2009043889A2 (en)	2007-10-04	2009-04-09	Merck Serono S.A.	Oxadiazole derivatives
BRPI0817597A2 (pt) *	2007-10-04	2015-04-07	Merck Serono Sa	Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos
US8551463B2 (en)	2007-10-22	2013-10-08	Living Proof, Inc.	Hair care compositions and methods of treating hair
US8202856B2 (en) *	2007-12-21	2012-06-19	Merck Serono Sa	Triazole oxadiazoles derivatives
ES2389042T3 (es) *	2008-03-06	2012-10-22	Actelion Pharmaceuticals Ltd.	Compuestos de piridina
AU2009220893A1 (en)	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Novel aminomethyl benzene derivatives
WO2010085582A1 (en)	2009-01-23	2010-07-29	Bristol-Myers Squibb Company	Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
CN102361868A (zh)	2009-01-23	2012-02-22	百时美施贵宝公司	作为1-磷酸-鞘氨醇激动剂的吡唑-1，2，4-噁二唑衍生物
EP2382212B1 (en)	2009-01-23	2014-07-16	Bristol-Myers Squibb Company	Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
SG178042A1 (en)	2009-07-16	2012-03-29	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives
US8399451B2 (en)	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
CN103119038B (zh)	2010-04-23	2016-05-04	百时美施贵宝公司	作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺
US8318783B2 (en)	2010-04-27	2012-11-27	Allergan, Inc.	3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators
JP5869579B2 (ja) *	2010-09-24	2016-02-24	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
SI2665720T1 (sl)	2011-01-19	2015-08-31	Actelion Pharmaceuticals Ltd.	Derivati 2-metoksi-piridin-4-ila
US9073881B2 (en) *	2011-09-23	2015-07-07	Hoffmann-La Roche Inc.	Benzoic acid derivatives
US10385043B2 (en)	2015-05-20	2019-08-20	Idorsia Pharmaceuticals Ltd	Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
US20230398099A1 (en) *	2020-11-09	2023-12-14	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
EP4050002A1 (en) *	2021-02-26	2022-08-31	First Health Pharmaceuticals B.V.	Anti-proliferative agents

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH623971B5 (de)	1976-06-04	1982-01-15	Hoechst Ag	Verfahren zur herstellung neuer benzofuranderivate und deren verwendung als optische aufheller.
US4135910A (en) *	1977-05-12	1979-01-23	Monsanto Company	Oxadiazol-3-yl-benzoates as plant growth regulants
DE4320801A1 (de)	1993-06-23	1995-01-05	Fahlberg List Pharma Gmbh	2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
DE19643037A1 (de) *	1996-10-18	1998-04-23	Boehringer Ingelheim Kg	Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
AUPP999799A0 (en)	1999-04-27	1999-05-20	Fujisawa Pharmaceutical Co., Ltd.	New compound
ES2887054T3 (es)	2003-04-11	2021-12-21	Ptc Therapeutics Inc	Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
AU2004240586A1 (en) *	2003-05-15	2004-12-02	Merck & Co., Inc.	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
US20070043014A1 (en) *	2003-10-01	2007-02-22	Merck & Co., Inc.	3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US7605171B2 (en) *	2003-12-17	2009-10-20	Merck & Co., Inc.	(3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2005108370A1 (ja) *	2004-04-16	2005-11-17	Ajinomoto Co., Inc.	ベンゼン化合物
BRPI0511676A (pt)	2004-05-29	2008-01-08	7Tm Pharma As	uso medicinal de ligandos receptores
AU2005299851B2 (en) *	2004-10-22	2011-03-17	Merck Sharp & Dohme Corp.	2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
EP1893591A1 (en) *	2005-06-08	2008-03-05	Novartis AG	POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
WO2007043400A1 (ja)	2005-10-07	2007-04-19	Kissei Pharmaceutical Co., Ltd.	含窒素芳香族複素環化合物およびそれを含有する医薬組成物
TWI404706B (zh) *	2006-01-11	2013-08-11	Actelion Pharmaceuticals Ltd	新穎噻吩衍生物
JP2009269819A (ja)	2006-08-25	2009-11-19	Asahi Kasei Pharma Kk	アミン化合物
JP2010504932A (ja)	2006-09-29	2010-02-18	ノバルティスアーゲー	抗炎症および免疫抑制特性を有するオキサジアゾール誘導体
AU2007334436A1 (en)	2006-12-15	2008-06-26	Abbott Laboratories	Novel oxadiazole compounds
EP2014653A1 (en)	2007-06-15	2009-01-14	Bioprojet	Novel dicarboxylic acid derivatives as S1P1 receptor agonists
BRPI0817597A2 (pt) *	2007-10-04	2015-04-07	Merck Serono Sa	Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos
WO2009043889A2 (en)	2007-10-04	2009-04-09	Merck Serono S.A.	Oxadiazole derivatives

2008
- 2008-10-01 BR BRPI0817597 patent/BRPI0817597A2/pt not_active IP Right Cessation
- 2008-10-01 CN CN200880110507.5A patent/CN101815707B/zh not_active Expired - Fee Related
- 2008-10-01 CN CN201410603560.6A patent/CN104478821B/zh not_active Expired - Fee Related
- 2008-10-01 EA EA201070423A patent/EA201070423A1/ru unknown
- 2008-10-01 EP EP08804975.4A patent/EP2193126B1/en active Active
- 2008-10-01 MX MX2010003614A patent/MX2010003614A/es not_active Application Discontinuation
- 2008-10-01 WO PCT/EP2008/063185 patent/WO2009043890A1/en not_active Ceased
- 2008-10-01 JP JP2010527450A patent/JP5727223B2/ja not_active Expired - Fee Related
- 2008-10-01 AU AU2008306886A patent/AU2008306886B2/en not_active Ceased
- 2008-10-01 KR KR1020107009974A patent/KR20100083814A/ko not_active Withdrawn
- 2008-10-01 ES ES08804975.4T patent/ES2547877T3/es active Active
- 2008-10-01 CA CA2696829A patent/CA2696829C/en not_active Expired - Fee Related
- 2008-10-01 US US12/675,254 patent/US8404676B2/en not_active Expired - Fee Related
- 2008-10-03 AR ARP080104332A patent/AR068730A1/es not_active Application Discontinuation
2010
- 2010-02-19 ZA ZA2010/01217A patent/ZA201001217B/en unknown
- 2010-03-16 IL IL204520A patent/IL204520A/en not_active IP Right Cessation
2012
- 2012-12-12 US US13/711,934 patent/US8889668B2/en not_active Expired - Fee Related
2014
- 2014-09-26 JP JP2014197234A patent/JP2015025001A/ja not_active Withdrawn
2016
- 2016-05-19 JP JP2016100693A patent/JP6224771B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP6224771B2 (ja)	2017-11-01
US20130109676A1 (en)	2013-05-02
CN101815707A (zh)	2010-08-25
AU2008306886A1 (en)	2009-04-09
JP5727223B2 (ja)	2015-06-03
ES2547877T3 (es)	2015-10-09
WO2009043890A1 (en)	2009-04-09
KR20100083814A (ko)	2010-07-22
MX2010003614A (es)	2010-04-21
JP2010540593A (ja)	2010-12-24
IL204520A0 (en)	2010-11-30
CN101815707B (zh)	2015-09-02
CN104478821A (zh)	2015-04-01
AU2008306886B2 (en)	2014-01-16
JP2016169223A (ja)	2016-09-23
EA201070423A1 (ru)	2010-10-29
US20100305104A1 (en)	2010-12-02
CN104478821B (zh)	2016-09-28
AR068730A1 (es)	2009-12-02
ZA201001217B (en)	2011-04-28
JP2015025001A (ja)	2015-02-05
EP2193126B1 (en)	2015-06-24
CA2696829A1 (en)	2009-04-09
EP2193126A1 (en)	2010-06-09
US8889668B2 (en)	2014-11-18
IL204520A (en)	2016-04-21
US8404676B2 (en)	2013-03-26
CA2696829C (en)	2017-07-04

Publication	Publication Date	Title
BRPI0817597A2 (pt)	2015-04-07	Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos
BRPI0818533A2 (pt)	2017-06-06	composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BRPI0819218A2 (pt)	2015-05-05	Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0813237A2 (pt)	2014-12-23	Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0817200A2 (pt)	2017-01-31	composições oftálmicas sólida e uso de compostos para fabricação de medicamento
BRPI0816991A2 (pt)	2015-03-24	Formulação, processo para preparar a mesma, e, usos de uma composição antimicrobiana e de uma formulação
BRPI0922619A2 (pt)	2016-09-13	compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento
MA30236B1 (fr)	2009-03-02	Nouvelle composition pharmaceutique
BRPI0816331A2 (pt)	2015-04-14	Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
CL2008000403A1 (es)	2008-08-18	Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
BR112012003637A2 (pt)	2017-04-25	"compostos de ligação de proteína de choque térmico, composições, e métodos para preparar e usar os mesmos"
BRPI1009481A2 (pt)	2016-03-01	compostos de 2-acetamido-5-aril-1,2,4-triazolonas substituídas, seu processo de preparação, seu uso e medicamento compreendendo os mesmos
BRPI0814163A2 (pt)	2015-01-20	Processo para a preparação de compostos, forma cristalina, e, composição farmacêutica
BRPI0717638A2 (pt)	2013-11-12	Anticorpors e imunoconjugados e usos para os mesmos
BRPI0911685A2 (pt)	2015-10-13	composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0914927A2 (pt)	2017-06-20	composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto
BRPI0905717A2 (pt)	2015-07-14	Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0814611A2 (pt)	2015-01-27	Composição, processo para preparar uma composição, e, uso de uma composição
BRPI0814821A2 (pt)	2015-02-03	Composto, composição farmacêutica, e, processo para preparar um composto
BRPI0818459A2 (pt)	2015-04-14	Composição farmacêutica adequada para uso oftálmico.
BRPI0815360A2 (pt)	2015-02-10	Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto
BRPI0607423A2 (pt)	2016-11-08	forma microcristalina de um composto, processo para a preparação da mesma, uso de uma forma microcristalina, composição farmacêutica e processo para a preparação da mesma, e, produto
EP2116242A4 (en)	2013-02-13	NEW PHARMACEUTICAL COMPOSITION
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.